The U.S. Food and Drug Administration (FDA) has announced that they are adding staff and rolling out policy changes aimed at advancing the development of safe and effective cell and gene therapies. [1] The announcement came in the form of a press release on January 15th, citing that the new policies are a response to the current surge in cell and gene therapy products that the agency is handling. Based on the number of investigational new drug (IND) applications being submitted, the FDA projects a significant rise in the number of therapies that will be approved over the next few years:
Gene and cellular therapy is different from the drugs that have come before -- and so are the dangers. Guidance from the FDA is available to avoid pitfalls.
The FDA has an agency that provides researchers with assistance towards taking mesenchymal stem cells to clinical trials and approvals.
